Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We maintained our Neutral recommendation on Coca-Cola Enterprises Inc. ( CCE - Analyst Report ) following appraisal of second quarter 2012 results.
Coca-Cola Enterprises’ second quarter 2012 adjusted earnings of 73 cents per share were in line with the Zacks Consensus Estimate. However, earnings declined 4% over the prior-year quarter due to currency headwinds and volume declines.
During the quarter, net sales declined 8.5% to $2.21 billion. Volumes were down 6% in the quarter due to increased retail prices resulting from the French excise tax increase, strong prior-year quarter comparisons, weather headwinds throughout the quarter and ongoing macroeconomic softness.
Despite the tough quarter, volume softness and economic challenges in Europe, the company’s underlying guidance remained largely unchanged, which is a strong positive. The company expects adjusted earnings per diluted share to be within $2.18 to $2.24; including currency headwinds of 10%. The guidance represents growth of over 10% on a currency neutral basis, which is higher than prior expectations of currency neutral earnings per share increasing by 10%.
The solid marketing programs for the London Olympics together with easing comparisons, cost-saving efforts and share buybacks are expected to help the company meet its targets. Overall, we are optimistic about the company’s long-term fundamentals.
Coca-Cola Enterprise is one of the largest Coca-Cola bottlers in the world. The company is the sole licensed bottler for The Coca-Cola Company’s (KO) products in Western Europe. Over 90% of the company’s sales volume comprises products of The Coca-Cola Company. The collaboration helps the company to create and develop new brands, market products in an efficient manner and also maximize efficiency.
The company distributes one of the world's most recognized brand portfolios, with growing core brands led by the Coca-Cola trademark. Moreover, the company continuously focuses on growing value of existing brands. The company is also slowly diversifying its product portfolio beyond the colas which are witnessing sluggish volume growth in comparison to other emerging categories like energy and still beverages. Further, the company focuses on innovation in new brands, flavor extensions, new packaging or sweeteners. These initiatives ensure customer satisfaction and thereby generate additional revenue opportunities for the company.
Read the full reports :
Analyst Report on CCE